Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers
Cancers · 24.08.2023 · 15 (17) · 4245
DOI: 10.3390/cancers15174245 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 24.08.2023. Verfasst von Javier Ros und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Vall d'Hebron University Hospital, 08035 Barcelona, Spain. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Microsatellite instability (MSI) is a biological condition associated with inflamed tumors, high tumor mutational burden (TMB), and responses to immune checkpoint inhibitors. In colorectal cancer (CRC), MSI tumors are found in 5% of patients in the metastatic setting and 15% in early-stage disease. Following the impressive clinical activity of immune checkpoint inhibitors in the metastatic setting, associated with deep and long-lasting responses, the development of immune checkpoint inhibitors has expanded to early-stage disease. Several phase II trials have demonstrated a high rate of pathological complete responses, with some patients even spared from surgery. However, in both settings, not all patients respond and some responses are short, emphasizing the importance of the ongoing search for accurate biomarkers. While various biomarkers of response have been evaluated in the context of MSI CRC, including B2M and JAK1/2 mutations, TMB, WNT pathway mutations, and Lynch syndrome, with mixed results, liver metastases have been associated with a lack of activity in such strategies. To improve patient selection and treatment outcomes, further research is required to identify additional biomarkers and refine existing ones. This will allow for the development of personalized treatment approaches and the integration of novel therapeutic strategies for MSI CRC patients with liver metastases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology Department, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
- Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
ORCID-Profile: Javier Ros, Iosune Baraibar, Marta Rodriguez, Josep Tabernero
Zitieren
APA
Ros, J., Baraibar, I., Saoudi, N., Rodriguez, M., Salvà, F., Tabernero, J., & Élez, E. (2023). Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers. Cancers, 15(17), 4245. https://doi.org/10.3390/cancers15174245
Vancouver
Ros J, Baraibar I, Saoudi N, Rodriguez M, Salvà F, Tabernero J, et al. Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers. Cancers. 2023;15(17):4245. doi:10.3390/cancers15174245
BibTeX
@article{Ros2023,
author = {Ros, Javier and Baraibar, Iosune and Saoudi, Nadia and Rodriguez, Marta and Salvà, Francesc and Tabernero, Josep and Élez, Elena},
title = {Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers},
journal = {Cancers},
year = {2023},
volume = {15},
number = {17},
pages = {4245},
doi = {10.3390/cancers15174245}
}
EUVIMED